A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

Recruiting

Phase 1

Phase 2

NXT007A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

Sponsor:

Hoffmann-La Roche

Code:

NCT05987449

Conditions

Hemophilia A

Eligibility Criteria

Sex: Male

Age: 2 - 59

Healthy Volunteers: Not accepted

Interventions

NXT007

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-13. This information was provided to ClinicalTrials.gov by Hoffmann-La Roche on 2026-07-06.